Legend Biotech names ex-Novartis exec as CEO
Cell therapy developer Legend Biotech has named Ingrid Zhang as its new chief executive, ending its search for new leadership.
TikTok parent ByteDance raises cash for drug AI spinout Anew
Chinese tech giant ByteDance, best known as the parent of TikTok, has completed a $290m financing for its AI drug discovery spinout Anew Labs.
AI spots drugs that may be repurposed for priority pathogen
Researchers have used AI algorithms to sift through thousands of drug molecules and identify some with activity against problem pathogen S pneumoniae.
FDA unveils framework for its expedited IND pilot
The FDA has published the design of its expedited Investigational New Drug pilot, part of a plan to restore US competitiveness in clinical research.
FDA backs Curium's Bexlutry as 1st 'radioligand equivalent'
Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
RNA-Targeted Small Molecules: From Discovery to Clinic
Leading pharma, biotech and academic experts discuss the future of RNA therapeutics.
Novel CNS Biomarkers Summit Europe
Europe is rapidly becoming a hub for next-generation CNS biomarker innovation
Who's Speaking at the DIA-MHRA Global Summit 2026?
See who's speaking when regulators and industry convene at the DIA-MHRA Global Summit
4th Cell Therapy for Autoimmune Disease Summit
Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access
10th Complement-Based Drug Development Summit
Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications